AIM:To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for me......

AIM: To evaluate the genetic and epigenetic inactivation mechanism of the RASSF1A tumor suppressor gene at 3p21.3 in ext......

Recent histological and molecular characterization of cholangiocarcinoma(CCA) highlights the heterogeneity of this cance......